tiprankstipranks
Trending News
More News >

Clover Biopharmaceuticals to Review 2024 Financial Results and Dividend

Story Highlights
Clover Biopharmaceuticals to Review 2024 Financial Results and Dividend

Don’t Miss TipRanks’ Half-Year Sale

An update from Clover Biopharmaceuticals Ltd. ( (HK:2197) ) is now available.

Clover Biopharmaceuticals Ltd. announced that its board of directors will convene on March 24, 2025, to review and approve the company’s annual financial results for 2024 and consider the declaration of a final dividend. This meeting is significant as it will provide insights into the company’s financial health and potential shareholder returns, impacting its market positioning and stakeholder confidence.

More about Clover Biopharmaceuticals Ltd.

Clover Biopharmaceuticals Ltd. operates in the biotechnology industry, focusing on the development of innovative vaccines and biologic therapeutics. The company is known for its commitment to addressing global health challenges and enhancing healthcare outcomes.

YTD Price Performance: 35.42%

Average Trading Volume: 1,509,092

Technical Sentiment Consensus Rating: Hold

Current Market Cap: HK$421.5M

See more data about 2197 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1